To improve the survival rate of non-small cell lung cancer (LuCa) patients, an economically efficient screening method without radiation hazard is preferred. Based on our previously reported potential serum biomarkers for predicting survival and differentiating LuCa stages and types, we investigated the potential for these biomarkers to be used for early detection screening using LuCa serum samples from patients prior to their diagnoses and compared with those measured at the time of diagnosis. If developed, our findings could be used as a minimally-invasive early diagnosis scheme.
This abstract and the presentation materials are available to members only; a login is required.